In its upcoming report, McKesson (MCK) is predicted by Wall Street analysts to post quarterly earnings of $8.92 per share, reflecting an increase of 26.2% compared to the same period last year. Revenues are forecasted to be $104.66 billion, representing a year-over-year increase of 11.8%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific McKesson metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenue- Prescription Technology Solutions' will reach $1.39 billion. The estimate indicates a change of +9.7% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Medical-Surgical Solutions' will reach $3.02 billion. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts expect 'Adjusted Operating Profit- Medical-Surgical Solutions' to come in at $246.33 million. The estimate compares to the year-ago value of $243.00 million.
The consensus estimate for 'Adjusted Operating Profit- Prescription Technology Solutions' stands at $245.96 million. The estimate compares to the year-ago value of $218.00 million.
View all Key Company Metrics for McKesson here>>>
Over the past month, shares of McKesson have returned +8.8% versus the Zacks S&P 500 composite's +2.1% change. Currently, MCK carries a Zacks Rank #1 (Strong Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McKesson Corporation (MCK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
